2023 Early Hearing Detection & Intervention Conference
March 5-7, 2023 • Cincinnati, OH
8/22/2022 | 10:45 AM - 11:10 AM | Cytomegalovirus Screening Outcomes from the ValEAR Trial | Confederation II/III
Cytomegalovirus Screening Outcomes from the ValEAR Trial
Objective: Determine the positivity rates for early cCMV testing from multiple institutions. Methods: Birth hospitals participating in the NIH funded ValEAR clinical trial were examined to determine the rates of CMV positivity associated with three different screening or testing methods: universal testing, hearing targeted-CMV testing (HT-CMV), and dried blood spot testing (DBS). Results: Eighty-two birth hospitals were surveyed from February 2019 to December 2021. Seven thousand six hundred forty-nine infants received universal CMV screening, 8641 infants received hearing targeted-CMV testing (HT-CMV), and 526 infants underwent a dried blood spot (DBS) CMV PCR assay. The rate of CMV positivity was 0.5%, 1.4% and 7.6% respectively. Screening outcomes with HT-CMV was unchanged before and after March 2020. For HT-CMV approach, those sites with a process in place for testing and to contact CMV positive patients were associated with successful outcomes. Conclusion: Rates of CMV positivity differ between the three screening approaches. These sites were able to maintain testing despite COVID-19. Factors associated with successful testing were identified.
- What is the positivity rate from 3 different approaches to identify infants with congenital CMV infection?
- What were the effects of any on CMV outcomes from the COVID-19 pandemic?
- What factors if any are associated a successful hearing targeted CMV testing program?
Presentation:
This presentation has not yet been uploaded.
Handouts:
Handout is not Available
Transcripts:
CART transcripts are NOT YET available, but will be posted shortly after the conference
Presenters/Authors
Albert Park
(), albert.park@hsc.utah.edu;
Dr. Park is the chief for Pediatric Otolaryngology at the University of Utah. He is the principal investigator for an NIH funded multi-institutional clinical trial to determine whether the antiviral drug, valganciclovir can improve hearing outcomes for children with cytomegalovirus (CMV), a very common and understudied cause of childhood hearing loss.He also established a CMV working group comprising of pediatric genetics, infectious disease, otolaryngology, audiology, neurology, department of health and ARUP laboratories to streamline clinical and research initiatives in this field.
ASHA DISCLOSURE:
Financial -
Nonfinancial -